Xichun Hu

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

Xichun Hu, Jian Zhang, Binghe Xu et al. · International Journal of Cancer · 2014 · 267 citations · Full text

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Zefei Jiang, Wei Li, Xichun Hu et al. · The Lancet Oncology · 2019 · 261 citations

Breast Oncology, Medicine, Pharmacology +8

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

Xichun Hu, Jun Cao, Wenwei Hu et al. · BMC Cancer · 2014 · 233 citations · Full text

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 152 citations · Full text

Breast Oncology, Medicine, Pharmacology +7

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Leiping Wang, Qunling Zhang, Jian Zhang et al. · BMC Cancer · 2011 · 145 citations · Full text